TipRanks on MSN3h
Royalty Pharma’s Internalization Strategy: Navigating Risks and Uncertainties Ahead of 2025 Transition
Royalty Pharma PLC (RPRX) has disclosed a new risk, in the Regulation category. The planned internalization of Royalty Pharma LLC by RP Holdings, ...
Recursion Pharmaceuticals files automatic mixed securities shelf
EST Recursion Pharmaceuticals (RXRX) files automatic mixed securities shelfMaximize Your Portfolio with Data Driven Insights:Leverage the ...
Supply Chain Management Review18h
The trade-off between affordability and availability
The trade-off between affordability and availability in pharmaceuticals arises because decisions affecting medicines’ prices also impact their market availability. Higher prices can increase supply by ...
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Royalty Pharma (RPRX), Waters (WAT) and OrganiGram Holdings (OGI)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Royalty Pharma (RPRX – Research Report), ...
Biotech/pharma M&A to pick up in 2025 once regulatory uncertainty declines
M&A in biotech and pharma is expected to surge in late 2024 as regulatory uncertainties ease. Discover trends, key players, and areas of high interest.
Royalty Pharma targets $3B share buyback and projects 4-9% growth in 2025 portfolio receipts
Pablo Legorreta, CEO, highlighted strong 2024 performance, with Portfolio Receipts reaching $2.8 billion, at the high end of guidance and representing 13% growth in Royalty Receipts. He noted this ...